Jacobio Pharma meeting takeaways: pan-KRAS focused on 1L PDAC, watching for global Phase 3 in 2027

Overview

This report is Goldman Sachs' summary of meeting takeaways on Jacobio Pharma (1167.HK) after the 2026 China Healthcare Corporate Day, focusing on commercialization feedback for glecirasib, the clinical development path of JAB-23E73 in 1L PDAC, and the prospects for combination therapies in the RAS treatment field. The overall view is constructive, but it clearly points out that pipeline development and platform validation remain the main uncertainties.

Core views

The core views include three points: first, real-world feedback for glecirasib has been good, especially as lower gastrointestinal toxicity may improve patient compliance; second, JAB-23E73 is the company's core asset, and 1L PDAC is the highest priority in both China and global development plans; third, management believes RAS inhibitors have the opportunity to become backbone therapies in PDAC, but comparable data across different technology approaches remain limited at present.

Analysis framework

The report mainly analyzes management meeting discussions, clinical development plans, commercialization feedback, comparisons of similar RAS treatment mechanisms, and a risk-adjusted DCF valuation framework. Judgments on pipeline value incorporate trial stage, visibility of clinical data, combination therapy potential, and industry-average probabilities of success.

Methodology notes

• Valuation methodsRisk-adjusted DCF

  12-month target price HK$9.14

  The target price is based on risk-adjusted DCF, using a 15% discount rate, a 2% terminal growth rate, and probability-of-success adjustments for different R&D stages.

• Clinical probabilityPoS adjustment

  Adjusting probability of success by R&D stage and clinical data

  The report states that PoS references industry-average success rates for different stages and is adjusted based on available clinical data to reflect the uncertainty of early-stage innovative drug assets.

• Factor comparisonGS Factor Profile

  Growth, Financial Returns, Multiple, Integrated

  The appendix explains that Goldman Sachs' factor profile compares individual stocks with the market and industry peers through growth, financial returns, valuation multiples, and integrated percentiles.

• M&A scenarioM&A Rank

  Potential acquisition probability score

  The appendix explains that Goldman Sachs uses an M&A rank of 1-3 to assess the probability of covered companies becoming acquisition targets, and includes it as a component of the target price when the rank is 1 or 2.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Jacobio Pharma (1167.HK)

  The company covered in the report, a Hong Kong-listed biopharmaceutical company.

  Strengths

  Has catalysts from commercialization feedback for glecirasib and RAS/KRAS pipeline assets such as JAB-23E73, with the target price implying substantial potential upside versus the disclosed price.

  Weaknesses

  Commercial manufacturing and sales track record remains limited, and the technology platform still requires further validation.

  Comparison

  The report compares it within the China innovative drug coverage universe and focuses on the potential differences of the RAS field relative to other technology approaches.

  Risks

  Development risks for SHP2/RAS assets, domestic and overseas competition, commercialization execution, and clinical development talent retention risks.

• glecirasib

  A KRAS G12Ci, with commercialization handled by commercial partner Allist.

  Strengths

  Positive feedback on sales ramp-up after NRDL coverage, with good physician and patient feedback; lower gastrointestinal toxicity may improve compliance.

  Weaknesses

  It still needs to be verified whether the FY26 Rmb300mn target can be achieved.

  Comparison

  2L+ NSCLC TAM is expected to be Rmb2.5-3bn, and the observed G12C mutation rate is 6-9%, higher than the prior understanding of below 5%.

  Risks

  Risks related to the pace of real-world volume growth, conversion of reimbursement coverage, and competition from similar KRAS G12C therapies.

• JAB-23E73

  The company's core pan-KRASi asset, currently focused on 1L PDAC.

  Strengths

  China ph1b/3 has been initiated, and the global pathway involves AZN first starting ph1 lead-in and advancing to ph3 in 2027, providing global development catalysts.

  Weaknesses

  It remains in the early stage of dose exploration and clinical validation, with limited visibility on efficacy and safety data.

  Comparison

  Compared with pan-RAS molecular glue, management believes pan-KRAS switch-II inhibitors may reduce skin and epithelial toxicity by preserving HRAS/NRAS inhibition, and the small-molecule approach is also easier from a CMC perspective.

  Risks

  Clinical success rate in 1L PDAC, safety of combination regimens, timing of global trial initiation, and changes in the competitive landscape.

Key data

• Report date2026-06-26The report time was 26 June 2026 8:29PM HKT.
• 12-month target priceHK$9.14Based on risk-adjusted DCF.
• Disclosed priceHK$4.27Jacobio Pharma price listed in the company-specific disclosure.
• glecirasib FY26 sales targetRmb300mnManagement said sales ramp-up after NRDL coverage has been encouraging.
• 2L+ NSCLC TAMRmb2.5-3bnAllist expects a larger market opportunity for 2L+ NSCLC.
• Observed G12C mutation rate6-9%Higher than the previously believed level of below 5%.
• China 1L PDAC ph1b enrollment sizeapproximately 20 patientsThe ph1b portion will explore multiple dose levels of JAB-23E73 in combination with AG.
• Global Phase 3 timing2027Management said AZN plans to first initiate a global ph1 lead-in, then advance to global ph3.
• Reference combination ORR92% ORR (N=11)From recent positive data of the PRMT5/pan-RAS combination vopimetostat/daraxonrasib in PDAC.

Impact & implications

If commercialization ramp-up for glecirasib and progress in the 1L PDAC trial for JAB-23E73 proceed smoothly, the company's valuation and market attention could benefit from clearer RAS pipeline catalysts. Conversely, if early clinical data, global trial pacing, or the safety of combination therapies fall short of expectations, the probability-of-success and target price assumptions in the risk-adjusted DCF could come under pressure.

Risks

• R&D risks related to SHP2/RAS assets.
• The technology platform still requires further validation.
• China and global markets may face competitive pressure.
• The company lacks a mature commercial manufacturing and sales track record.
• There are challenges in recruiting and retaining clinical development talent.
• If global trial updates for JAB-23E73 are slower than expected, market catalysts could weaken.

What to watch

• Monthly sales ramp-up for glecirasib after NRDL coverage and delivery against the FY26 Rmb300mn target.
• First patient enrollment, dose exploration results, and early safety signals from China 1L PDAC ph1b/3.
• The pace of AZN's global ph1 lead-in initiation, and whether the global ph3 progresses as planned in 2027.
• More data on potential combination therapies of JAB-23E73 with PRMT5 inhibitor, CLDN18.2 ADC, and others.
• Differences in efficacy, safety, and CMC between pan-KRAS switch-II inhibitors and pan-RAS molecular glue inhibitors.
• Whether potential BD deals, global market partnerships, and early asset PoC data exceed expectations.